Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well umbralisib and pembrolizumab work in treating patients
with classical Hodgkin lymphoma that has come back (relapsed) or does not respond to
treatment (refractory). Umbralisib may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of cancer cells to grow and spread. Giving umbralisib and pembrolizumab may work
better in treating classical Hodgkin lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
National Cancer Institute (NCI) TG Therapeutics, Inc.